Bicycle Therapeutics PLC (BCYC)

NASDAQ: BCYC · IEX Real-Time Price · USD
-0.73 (-4.64%)
May 26, 2022 3:57 PM EDT - Market closed

Company Description

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics.

Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4.

In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase.

Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications.

It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets.

Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Bicycle Therapeutics PLC
Bicycle Therapeutics Logo
CountryUnited Kingdom
IPO DateMay 23, 2019
SectorHealth Care
CEOKevin Lee

Contact Details

Babraham Hall
Cambridge, Cambridgeshire CB22 3AT
United Kingdom
Phone44 1223 261 503

Stock Details

Ticker SymbolBCYC
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$14.00
CIK Code1761612

Key Executives

Dr. Kevin Lee M.B.A., Ph.D.Chief Executive Officer and Executive Director
Lee H. Kalowski M.B.A., MBAPresident and Chief Financial Officer
Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSECo-Founder, Non-Executive Director and Member of Scientific Advisory Board
Dr. Michael Skynner Ph.d., Ph.D.Chief Technology Officer
Dr. Christian HeinisScientific Founder
Alistair MilnesChief Operating Officer
Dr. Nicholas Keen Ph.D.Chief Scientific Officer
David E. Borah CFAVice President of Capital Markets and Investor Relations
Zafar QadirGeneral Counsel
Dr. Gillian LangfordHead of Clinical and Project Management

Latest SEC Filings

May 5, 202210-QQuarterly report [Sections 13 or 15(d)]
May 5, 20228-KCurrent report
May 2, 2022SC 13GStatement of acquisition of beneficial ownership by individuals
Apr 29, 2022DEF 14AOther definitive proxy statements
Apr 15, 2022PRE 14AOther preliminary proxy statements
Apr 12, 20228-KCurrent report
Mar 29, 20224Statement of changes in beneficial ownership of securities
Mar 29, 20223/AInitial statement of beneficial ownership of securities
Mar 14, 2022SC 13D/AGeneral statement of acquisition of beneficial ownership
Mar 1, 2022S-8Securities to be offered to employees in employee benefit plans
View All SEC Filings